Tryton Medical, Inc. Broadcasts Successful Live Case Using Company’s Side Branch Stent™ to Definitively Treat Bifurcation Lesions at TCT 2009

DURHAM, N.C. & San Francisco–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to
definitively treat bifurcation lesions, announced today the transmission
of a live satellite feed of a clinical case performed in the United
Kingdom to an audience of more than 1,000 interventional cardiologists
at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San
Francisco.

The procedure was performed at The London Chest Hospital by Simon
Kennon, M.D., FRCP.

“The Tryton stent design means that it is both deliverable and
re-crossable,” said Dr. Kennon. “In my practice, it is now the default
two-stent strategy for bifurcations.”

“We are pleased that the Tryton Stent System was selected to be featured
as one of the live case demonstrations at TCT, one of the world’s
premier conferences for interventional cardiologists,” said J. Greg
Davis, president and CEO of Tryton Medical. “We have had a great deal of
interest about the product at our booth on the exhibition floor at the
meeting, and it has been a pleasure to share our enthusiasm for the
Tryton solution with the many international clinicians attending TCT
this year.

“By the end of next week more than 300 Tryton Stent Systems will have
been used to treat some of the most difficult cases in interventional
cardiology.”

About the Tryton Side Branch Stent System

The Tryton Side Branch Stent System is designed to offer a dedicated
strategy for treating atherosclerotic lesions in the side branch at the
site of a bifurcation. These areas of the vascular system are a common
location for plaque and are particularly challenging to treat with
currently available stent systems. Approximately twenty percent of
patients treated for coronary artery disease have diseased bifurcated
lesions.

Tryton’s highly deliverable cobalt chromium stent is deployed in the
side branch artery using a standard single-wire balloon-expandable stent
delivery system. A conventional drug-eluting stent is then placed in the
main vessel.

The Tryton Side Branch Stent System demonstrated excellent six-month
clinical results in a first-in-man study of the system in 30 patients,
with no restenosis occurring in the side branch artery. The stent system
has received CE Mark approval in Europe and is not approved in the
United States.

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is a leading developer of
novel stent systems for the treatment of bifurcation lesions. The
company`s Side Branch Stent System, approved for sale in Europe, is
designed to offer a dedicated strategy for treating these challenging
cases. The privately held company is backed by Spray Ventures, PTV
Sciences, and RiverVest Ventures. For more information please visit trytonmedical.com.